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A B S T R A C T
Lipid dysregulation is a common hepatic adverse outcome after exposure to toxic drugs and chemicals. A donor-
free rat hepatocyte-like (B-13/H) cell was therefore examined as an in vitro model for investigating mechanisms.
The B-13/H cell irreversibly accumulated triglycerides (steatosis) in a time- and dose-dependent manner when
exposed to fatty acids, an effect that was potentiated by the combined addition of hyperglycaemic levels of
glucose and insulin. B-13/H cells also expressed the LXR nuclear receptors and exposure to their activators –
T0901317 or GW3965 – induced luciferase expression from a transfected LXR-regulated reporter gene construct
and steatosis in a dose-dependent manner with T0901317. Exposing B-13/H cells to a variety of cationic am-
phiphilic drugs – but not other hepatotoxins – also resulted in a time- and dose-dependent accumulation of
phospholipids (phospholipidosis), an effect that was reduced by over-expression of lysosomal phospholipase A2.
Through application of this model, hepatotoxin methapyrilene exposure was shown to induce phospholipidosis
in both B-13 and B-13/H cells in a time- and dose-dependent manner. However, methapyrilene was only toxic to
B-13/H cells and inhibitors of hepatotoxicity enhanced phospholipidosis, suggesting phospholipidosis is not a
pathway in toxicity for this withdrawn drug. In contrast, pre-existing steatosis had minimal effect on metha-
pyrilene hepatotoxicity in B-13/H cells. These data demonstrate that the donor free B-13 cell system for gen-
erating hepatocyte-like cells may be employed in studies of fatty acid- and LXR activator-induced steatosis and
phospholipidosis and in the dissection of pathways leading to adverse outcomes such as hepatotoxicity.
1. Introduction
The liver is a common target organ for drug- and chemical-mediated
toxicity and the hepatocyte is most frequently the cell that is injured, in
part, because of its active transport and first pass metabolism of drugs
and chemicals (Wallace et al., 2008). The hepatocyte also plays a
prominent role in the control of body’s metabolism and this includes
lipid homeostasis. Hepatocytes synthesise triglycerides; synthesise li-
poprotein components used to transport lipids throughout the body and
are capable of active cholesterol and bile acid synthesis (Nguyen et al.,
2008). Hepatocytes are also active in fatty acid oxidation, notably,
through an up-regulation of peroxisomal fatty acid oxidation
(Chamouton and Latruffe, 2012). A dysregulation in lipid homeostasis
in hepatocytes is therefore often observed in the liver as an early re-
sponse to exposure to toxic drugs and chemicals (Klaunig et al., 2003).
The B-13 cell line – originally cloned from the rat exocrine pan-
creatic cancer cell line AR42J (Mashima et al., 1996) – could offer a
potential route to delivering a cost-effective, simple solution to the
production of functional hepatocytes in vitro (for a full description of its
derivation, see Probert et al., 2015). The B-13 cell is readily expandable
in simple culture medium, does not require an extensive array of re-
combinant growth factors to retain its phenotype nor require sub-cul-
ture from non-progenitor cell types (such as fibroblasts) in its expan-
sion, in contrast to pluripotent stem cells (Probert et al., 2015).
Furthermore, B-13 cells do not require an extensive array of re-
combinant growth factors and/or other signalling inhibitor treatments
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to direct them to become hepatocytes. Exposure to a single gluco-
corticoid hormone is all that is required (Shen et al., 2000; Wallace
et al., 2011). Critically, in contrast to stem cell-derived hepatocyte-like
cells which generally only form a foetal level of hepatic differentiation,
B-13/H cells express many adult hepatocyte genes at adult hepatocyte
levels (Marek et al., 2003; Fairhall et al., 2013a, 2016). With respect to
xenobiotic metabolism, B-13/H cells express functional CO-spectro-
photometrically-detectable levels of many cytochrome P450s including
Cyp1a1, Cyp2a1/2, Cyp2c6, Cyp2c11, cyp2c13, Cyp3a, Cyp3a2,
Cyp3a9 and Cyp7a1 (Probert et al., 2015). A variety of phase 2 genes
(sulfotransferases, UDP glucuronyl transferases, glutathione-S-trans-
ferases) have also been shown to be functional (Probert et al., 2015,
2016). A further advantage of B-13/H cells over other potential hepa-
tocyte models such as stem cell derived hepatocytes, is that for reasons
unknown, B-13/H cells remain differentiated for several weeks despite
their culture on simple plastic cultureware. Primary hepatocytes and
stem cell-derived hepatocyte-like cells (once driven toward a hepato-
cyte phenotype) still then undergo de-differentiation (Wallace et al.,
2010a). The B-13 cell line – being freely available – therefore provides a
cost-effective, reliable and repeatable model system in which liver
functions may be studied. Although a number of studies have been
completed with regard to B-13/H cells, xenobiotic metabolism and
hepatoxicity, lipid dysregulation has not been investigated.
Steatosis defines primarily an accumulation of triglycerides and is
an early adverse response to injury by hepatoxins such as carbon tet-
rachloride (Weber et al., 2003) or ethanol (Mathews et al., 2014; Louvet
and Mathurin, 2015). It has been considered to be a relatively benign
reversible response to some toxic stresses such as alcohol exposure.
However, more recently it has become clear that it may be a critical
early event in alcoholic liver disease pathogenesis and in non-alcohol
dependent liver diseases such as non-alcoholic steatohepatitis (NASH)
(Day, 2012).
The liver X receptor (LXR) is a member of the nuclear receptor gene
superfamily of ligand-activated transcription factors (Jakobsson et al.,
2012). Two closely related genes have been identified, LXRα and LXRβ.
LXRβ is widely expressed whereas LXRα expression is restricted and
highest in the liver. The LXRs are activated by oxysterols and have been
considered as drug targets for treatment of hypercholesterolaemia.
However, LXR activator drugs also have the effect of promoting liver
steatosis (Repa et al., 2000; Cha and Repa, 2007).
Phospholipidosis is a lysosomal storage disorder characterised by
accumulation of phospholipids in tissues, such as the liver (Shayman
and Abe, 2013). Phospholipidosis is also seen in other tissues such as
the kidney and lung and is a common response to most typically ca-
tionic amphiphilic drugs. The precise mechanism(s) which lead to ac-
cumulation of phospholipids and whether this response is a critical
event in the mechanism of toxicity of causative drugs remain unclear
(Shayman and Abe, 2013).
In this paper, B-13/H cells have been examined for their ability to
re-capitulate lipid dysregulation in response to exposure to a variety of
drugs and/or metabolic stresses that cause steatosis and phospholipi-
dosis. We demonstrate that steatosis may be induced in B-13/H cells
through exposure to high concentrations of fatty acids; that B-13/H
cells express transcriptionally functional LXRα; that B-13/H cells are
susceptible to steatosis after treatment with LXR activators and that
exposing B-13/H cells to drugs which cause phospholiposis results in a
dose- and time-dependent increase in phospholipid accumulation.
Methapyrilene is a histamine H1 antagonist that was withdrawn after it
was shown to cause liver tumours in rats (Reznik-Schüller and Lijinsky,
1981; Fischer et al., 1983). Methapyrilene also causes periportal liver
injury in rats through a mechanism that requires metabolic activation
(Ratra et al., 1998a). Since the chemical structure of methapyrilene
shows all the attributes of a chemical that causes phospholidosis, the B-
13-based model was applied to investigate this effect for the first time
and to determine any role in hepatotoxicity.
2. Materials and methods
2.1. Plasmid constructs
The LXR responsive reporter gene construct, TK-LXRE-LUC (Willy
et al., 1995), was generously provided by Prof David Mangelsdorf,
Howard Hughes Medical Institute, University of Texas Southwestern
Medical Center, Dallas, TX 75390-9050. An expression construct en-
coding the human lysosomal phospholipase A2 (LPLA2, also known as
PLA2G15 or LYPLA3) cDNA sequence has been described previously
(Hiraoka et al., 2002). All other materials were purchased from Sigma-
Aldrich (Poole, UK) unless otherwise stated.
2.2. B-13 cell culture, treatments and transfection
B-13 cells (originally obtained from prof David Tosh, Bath
University, UK) were routinely cultured in low glucose (1 g/l)
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% (v/v)
fetal calf serum (FCS), 100 units/ml penicillin, 100 μg/ml streptomycin
and 0.584 g/l L-glutamine. Cells were incubated at 37 °C at 5% CO2 in
air in a humidified incubator and sub-cultured every 2–3 days by
trypsinization (1:3 split) or differentiated – when the cells had reached
approximately 40–50% confluency – to B-13/H cells via treatment with
10 nM dexamethasone (DEX) for 14 days, with media changes every
2–3 days (Marek et al., 2003). Hepatic phenotype (characterised by a
marked phenotypic change) was routinely confirmed through expres-
sion of Cyp2e1 transcripts by RT-PCR (see below). Cyp2e1 has been
shown to a sensitive marker of B-13 and both rodent and human pan-
creatic tissue conversion to an hepatocyte-like phenotype (Wallace
et al., 2009, 2010b; Fairhall et al., 2013b). Fatty acids (linoleic and
oleic acid) were dissolved in ethanol to give a stock with a final con-
centration of 200 mM each. Fatty acid-free bovine serum albumin was
dissolved in serum-free DMEM to give a final concentration of 0.8 mM.
The fatty acids were then added to the medium to give a final con-
centration of 2 mM fatty acids (total fatty acid:BSA ratio = 2.5:1). BSA
(Sigma) and ethanol were added to controls. All other chemical com-
pounds were added to media from 1000 fold molar concentrated DMSO
vehicle-solvated stocks (controls receiving 0.1% (v/v) DMSO), unless
otherwise stated.
For reporter gene studies, B-13 cells seeded in 24 well plates were
transfected with 0.25 μg DNA per well (pcDNA-empty or pcDNA-LPLA2
and a control plasmid (RL-TK, Promega) encoding the Renilla luciferase
protein under the regulation of a constitutive thymidine kinase pro-
moter) using polyethylenimine (PEI). Typically, for a 24 well plate,
12 μg of total DNA was added to 600 μl serum-free media and 72 μl of
1 mg/ml PEI solution and vortexed before being incubated at room
temperature for 15 min. This mixture was then add to 3.6 ml of serum-
free medium and 200 μl of this solution was added to each well and
incubated at 37 °C for 2 h. After this period, a further 300 μl of serum-
containing medium was then added and the cells further incubated for
22–46 h prior to further analyses.
2.3. Oil red stain and spectrophotometric quantification of triglyceride
accumulation
Cells cultured in 24 well plates were washed twice with PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4), fixed with
3.5% (w/v) formaldehyde in PBS for 30 min and then washed 3 times
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with PBS. The cells were then incubated with oil red O solution (84 mg
oil red O dissolved in 24 ml of isopropanol overnight at room tem-
perature prior to filtration and addition of 18 ml of water, incubation
overnight at 4 °C, double filtration and long term storage at 4 °C) at
room temperature for 5 min. Cells were then washed with water and
stored in PBS prior to image analysis. A quantitative analysis was then
performed through addition of a fixed volume of isopropanol to extract
bound lipid and removal of solvent for absorbance determination at
515 nm. Pre-treatment with isopropanol was employed to determine
lipid-free blank readings. The protein content in each well after removal
of isopropanol and washing with PBS using the Lowry method was used
to normalise lipid content to protein content. Note, that an increase in
phospholipidosis did not result in an increase in cell-associated oil red
stain (see Supp. Fig. S1 in the online version at DOI: http://10.1016/j.
tox.2017.05.014(http://dx.doi.org/10.1016/j.tox.2017.05.014)).
2.4. Triglyceride determination
Cells (combined from 6 wells from a 6 well plate) or tissue (approx.
50–100 mg) were washed with ice-cooled PBS. Cells were scraped into
PBS, quickly centrifuged to pellet the cells, the supernatant was dis-
carded and cells were re-suspended in ice-cooled 20 mM Tris buffer pH
7.4 with 100 mM KCl. Tissue was dabbed dry and added to 1 ml of ice-
cooled 20 mM Tris buffer pH 7.4 with 100 mM KCl. Samples were so-
nicated and an aliquot removed for protein analysis. One volume of the
remaining homogenate was added to 10 vol of lipid CM extraction
buffer (chloroform/methanol) (2:1 v/v) with 150 μM butylated hydro-
xytoluene. The samples were vortexed for 30 s, then centrifuged for
1 min at 13,000g and the upper organic layer retained in a fresh tube.
Homogenates were subjected to a repeat extraction and the second
organic extract combined with the first. Approximately 10 mg silica gel
(Sigma)/ml organic extract was added to bind phospholipid and after
pelleting and separation, organic extracts were evaporated at 37 °C
under a stream of nitrogen. Lipids were then re-suspended in 50 μl CM
extraction buffer prior to lipase treatment and glycerol determination
using a kit supplied by Abcam (Cambridge, UK) or analysis by TLC.
2.5. Phospholipid staining and quantification of phospholipid accumulation
Phospholipid in cells cultured in 24 well plates was stained using
LipidTOX (Thermofisher, UK) essentially according to the manu-
facturer’s instructions. Cells were then washed in PBS, fixed in 3.7%
(w/v) formaldehyde in PBS for 30 min, washed in PBS and then in-
cubated with 20 μM 4′6′-diamino-2-phenylindole (DAPI) for 10 min to
stain DNA. Cells were then washed and stored protected from light in
PBS at 4–8 °C prior to imaging using a Nikon Spinning Disk confocal
microscope or fluorescence determination at 595 nm excitation/
615 nm (LipidTOX) followed by 360 nm excitation/460 nm emission
(DAPI) for each well using a fluorescence plate reader. The LipidTOX
fluorescence was normalised to DNA using the DAPI fluorescence,
thereby controlling for cell number/well. Note, that an increase in
steatosis did not result in an increase in LipidTOX fluorescence, rather a
slight decrease (see Supp. Fig. S1 in the online version at DOI: http://
10.1016/j.tox.2017.05.014(http://dx.doi.org/10.1016/j.tox.2017.05.
014)).
2.6. Reverse transcriptase PCR (RT-PCR)
Total RNA was isolated from cells using TRIzol (Invitrogen, Paisley,
UK) following the manufacturer’s instructions. RT-PCR was performed
on total RNA essentially as previously described (Haughton et al.,
2006). The primer sequences are given in Supplementary Table S1 in
the online version at DOI: http://10.1016/j.tox.2017.05.014(http://dx.
doi.org/10.1016/j.tox.2017.05.014).
2.7. Western blotting
Western blotting was performed essentially as previously described
(Marek et al., 2005). The antibodies were purchased from Abcam and
were used at the dilution given in brackets:-rabbit anti-lysosome-asso-
ciated membrane protein 1 (LAMP1, 1:1000); rabbit anti-CYP2E1
(1:3000); rabbit anti-amylase (1:3000); mouse anti-β actin (1:3000);
rabbit anti-HA tag sequence (1:4000) and mouse anti-LXR (1:1000).
The relevant anti-IgG horseradish peroxidise conjugated secondary
antibody and ECL based chemiluminescent detection (GE Healthcare,
Amersham, UK) was used for detection using X-ray film.
2.8. Immunocytochemistry
Cells were washed twice with PBS then fixed using 2% (w/v) for-
maldehyde/0.2% glutaraldehyde in PBS for 20 min prior to a brief wash
with PBS and incubation with ice-cooled methanol on ice for 10 min.
After a brief rinse with PBS, cells were permeabilised and blocked
through incubation with 5% (v/v) FCS/0.1% (v/v) tween 20 in PBS for
20 min followed by 4 × 5 min washes with PBS. Anti-LAMP1 antibody
(Abcam) was incubated at a dilution of 1/200 in 0.5% (v/v) FCS in PBS
overnight at 4 °C, followed by washing and incubation with FITC-con-
jugated anti-rabbit IgG for 30 min. The cells were then washed
Fig. 1. Exposing B-13/H cells to fatty acids results in a time- and dose-dependent irreversible micro and macrosteatosis. A, RT-PCR for the indicated transcripts in the indicated cell types
or rat tissues. B (upper panels), B-13 and B-13/H cells were treated once without a medium change with medium supplemented where indicated with 2 mM fatty acids. After 3 days, cells
were fixed and stained with oil red and imaged under bright field illumination; (lower panel) B-13/H cells were treated daily with medium supplemented where indicated with 2 mM fatty
acids. At time zero, or 24 h after the last treatment, cells were fixed, stained with oil red and lipid accumulation quantified by extraction of oil red from stained cells and absorbance at
515 nm. Data are the mean and standard deviation of 3 separate determinations from the same experiment, typical of 3 separate experiments, *significantly different (two tailed) from
control treated cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test. C, Cells were treated once without a medium change with medium supplemented with the indicated
concentration of fatty acids. After 3 days, cells were fixed, stained with oil red and lipid accumulation quantified by extraction of oil red from stained cells and absorbance at 515 nm. Data
are the mean and standard deviation of 3 separate determinations from the same experiment, typical of 3 separate experiments, *significantly different (two tailed) from control treated
cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test. D, B-13/H cells were treated once without a medium change with medium supplementation as indicated. After
3 days, cells were fixed, stained with oil red and lipid accumulation quantified by extraction of oil red from stained cells and absorbance at 515 nm. Data are the mean and standard
deviation of 3 separate determinations from the same experiment, typical of n separate experiments, *significantly different (two tailed) from cells treated identically but with fatty acids
using the Student’s T test (p < 0.05). E, B-13/H cells were treated once without a medium change with medium supplemented with the indicated concentration of fatty acids. After
3 days, cells were fixed and stained with oil red and imaged under bright-field illumination. Right panels are exploded views of indicated region of left panels. F, quantification of the
number of microsteatotic and macrosteatotic droplets in cells. Data are the mean and standard deviation number of droplets in 20 cells for each concentration, randomly selected by an
investigator blinded to the treatments. *Significantly different (two tailed) from control treated cells using ANOVA (P > 0.95) followed by Bonferonni post hoc test. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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4 × 5 min in PBS, incubated with DAPI to stain DNA, washed in PBS
and imaged using a Nikon Spinning Disk confocal microscope.
2.9. Statistics
The student’s two-tailed T test was used to determine significant
difference between groups. Significance was achieved where p < 0.05.
For comparison of multiple groups, ANOVA was carried out and where
significant, differences between groups were determined using
Bonferroni–Holm method. Where p < 0.05, a significant difference
was assumed.
3. Results
3.1. B-13/H cells accumulate triglycerides in response to exposure to fatty
acids
B-13 and B-13/H cells express a variety of transcripts associated
with fatty acid uptake and synthesis although there may be an increase
in functional uptake capacity in B-13/H cells since there was an in-
duction from undetectable levels of CD36 (also known as fatty acid
translocase) in B-13/H cells (Fig. 1A). To determine whether B-13 and
B-13/H cells were capable of sequestering fatty acids and synthesising
and accumulating triglycerides, cells were exposed to 2 mM linoleic and
oleic acid fatty acids. Both B-13 and B-13/H cells showed evidence of
lipid accumulation as determined by oil red staining though this was
more marked in B-13/H cells (Fig. 1B, upper panels) and was associated
with a mean 16 fold increase in triglyceride content as determined by
glycerol quantitation in phospholipid-free lipid extracts treated with
lipase (Supp Fig. S2A in the online version at DOI: http://10.1016/j.tox.
2017.05.014(http://dx.doi.org/10.1016/j.tox.2017.05.014)). Lipid
accumulation increased with incubation time and resisted significant
reversal for at least 2 days when B-13/H cells were washed and
incubated in medium free of fatty acids (Fig. 1B, lower panel). The
increased variability of cell-associated oil red stain in un-washed cells
from day 3 after loading was likely associated with stress associated
with triglyceride accumulation since at time points beyond 4 days,
significant cell death was noted (data not shown). Fig. 1C demonstrates
that lipid accumulation in B-13/H cells was also dose-dependent.
Addition of biologically relatively high levels of insulin (100 nM,
typically levels in rat plasma are of the order 10−10 M, Bonner-Weir
et al., 1983) or glucose (25 mM, a hyperglycaemic concentration) had
no effect on lipid accumulation in B-13/H cells alone, or when
incubated separately with 2 mM fatty acids. However, a combination
of both insulin and glucose significantly increased the total
accumulation lipids when also incubated with 2 mM fatty acids (Fig.
1D).
Visual inspection of B-13/H cells suggested that the size of the lipid
droplets could be classified as falling within two sizes when incubated
with fatty acids (Fig. 1E). Incubating B-13/H cells at low concentrations
of fatty acids resulted in primarily small droplet formation whereas at
higher concentrations, both small and large droplets were formed
(Fig. 1F).
Since susceptibility to non-alcoholic fatty liver disease (NAFLD) in
man has been associated with a polymorphism in the Patatin-like
phospholipase domain-containing protein 3 (PNPLA3) gene (I148M
variant, rs738409, see Liu et al., 2014), the human and rat PNPLA3
cDNA sequences were aligned. Supp Fig. S3 in the online version at
DOI: http://10.1016/j.tox.2017.05.014(http://dx.doi.org/10.1016/j.
tox.2017.05.014) demonstrates that rodent and human PNPLA3 N-
terminal amino acid sequences show high homology and that the
isoleucine at position 148 (which is replaced by a methionine in
individuals with increased susceptibility to NAFLD) is conserved in
both wild type proteins. A segment of the PNPLA3 transcript in B-13/H
cells was amplified by RT-PCR, cloned and sequenced as outlined in the
Methods section. Eleven clones were sequenced and all were shown to
encode a wild type PNPLA3 transcript indicating, with greater than
95% confidence, that if susceptibility to NAFLD in the rat is similarly
affected by this polymorphism, then B-13 cells have a homozygous wild
type phenotype.
These data therefore demonstrate that B-13/H cells accumulate
lipid droplets when incubated with fatty acids in a time- and dose-de-
pendent manner, with the morphological appearance of primarily mi-
crosteatosis at lower concentrations increasing to additionally macro-
steatosis at higher concentrations. B-13/H cells also showed an increase
lipid accumulation when high fatty acid levels were also co-incubated
with both insulin and hyperglycaemic levels of glucose.
3.2. B-13/H cells have a functional LXR response
The LXR is a nuclear receptor that is activated by oxysterols and has
been considered as a potential drug target for the treatment of hy-
percholesterolaemia (Bełtowski, 2008; Calkin and Tontonoz, 2012).
LXR ligand activators such as T0901317 (Houck et al., 2004) and
GW3965 (Kotokorpi et al., 2007) promote reductions in circulating
cholesterol levels by inhibiting intestinal cholesterol absorption, sti-
mulating cholesterol efflux from cells/transport to the liver and con-
version to bile acids and biliary excretion (by the liver). However, these
chemicals also promote steatosis in the liver as an adverse effect (Repa
et al., 2000; Cha and Repa, 2007).
Fig. 2A demonstrates that B-13 and B-13/H cells express both LXRα
and LXRβ transcripts with a significant increase in expression of both
transcripts in the B-13/H phenotype. In contrast, the FXR nuclear re-
ceptor transcript (which regulates the expression of genes associated
with the synthesis of bile acids from cholesterol) is only expressed at
low levels in B-13/H cells (Fig. 2A). Fig. 2B indicates that LXR tran-
scripts are translated to low (undetectable) levels in B-13/H cells when
compared to rat hepatocytes. However, the LXR activators T0901317
and GW3965 readily transactivated an LXR regulated luciferase re-
porter construct suggestive of functional LXR transcriptional activity,
whereas the FXR agonist INT747 (Pellicciari et al., 2002) had no effect
(Fig. 2C). Exposing B-13/H cells to T0901317 resulted in significant
Fig. 2. B-13/H cells express the LXR and accumulate lipids in response to treatment with the LXR activator T0901317. A, RT-PCR for the indicated transcripts in RNA isolated from the
indicated cell/tissue. B, Western Blot for the indicated proteins in extracts from the indicated cell/tissue. Each lane contains 10 μg protein/lane. C, B-13/H cells were transfected with
pTK-LXRE3 luciferase and RL-TK constructs as outlined in the Methods section and after 48 h, cells were treated with the indicated compound and luciferase and renilla activities
determined after a further 24 h. Data are the mean and standard deviation of 6 separate determinations from the same experiment, typical of 3 separate experiments. D, B-13/H were
treated once for 3 days with medium supplemented with the indicated concentration of compound. After 3 days, cells were fixed, stained with oil red and lipid accumulation quantified by
extraction of oil red from stained cells and absorbance at 515 nm. Data are the mean and standard deviation of 3 separate determinations from the same experiment, typical of 2 separate
experiments, *significantly different (two tailed) from control treated cells using ANOVA (P > 0.95) followed by Bonferonni post hoc test. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
A.C. Leitch et al. Toxicology xxx (xxxx) xxx–xxx
6
(caption on next page)
A.C. Leitch et al. Toxicology xxx (xxxx) xxx–xxx
7
lipid accumulation whereas the weaker LXR activator GW3965 in-
creased levels but not to a statistically significant level (Fig. 2D).
However, it has been reported that GW3965 induced ADFP (a protein
residing at the surface of lipid droplets) in human but not in rat he-
patocytes and that this accounts for a lack of steatosis with GW3965 in
rat hepatocytes (Kotokorpi et al., 2007).
These data indicate that the adverse accumulation of lipids that
occurs in response to LXR accumulation may be modelled in B-13/H
cells although the response may be ablated due to low levels of LXR
expression.
3.3. B-13/H cells accumulate phospholipids in response to exposure to
cationic amphiphilic drugs
Phospholipidosis is a lysosomal storage disorder characterised by
accumulation of intracellular phospholipids (Shayman and Abe, 2013).
A large number of cationic amphiphilic drugs have been reported to
induce phospholipidosis, suggesting that they share a causative target
in cells. Fig. 3A and B demonstrates that B-13/H cells expressed readily
detectable levels of the lysosomal-associated membrane protein 1
(LAMP1), a lysosomal marker protein, by RT-PCR, Western blotting and
immunocytochemistry.
Fig. 3A suggest that whilst B-13 cells constitutively expressed
Lamp1 mRNA, Lamp1 protein was not readily detectable. However, in
response to DEX and conversion to B-13/H cells (as judged by expres-
sion of Cyp2e1), Lamp1 protein was induced to detectable levels and
was present at levels higher than in rat liver (Fig. 3A, lower panel). Note
that a variety of cytochrome P450s are expressed in B-13/H cells al-
though this is not the case with the fatty acid metabolising Cyp4a genes
which appear to contain several insertions and deletions in the locus
(Probert et al., 2015). Thus, B-13/H cells respond to peroxisome pro-
liferator activated receptor alpha ligands resulting in peroxisomal
proliferation, but expression of Cyp4a1, Cyp4a2 and Cyp4a3 is not
observed (Probert et al., 2015).
Treating both B-13 and B-13/H cells with the drug amiodarone,
which has been reported to induce phospholipidosis in variety of cell
types (Poucell et al., 1984; Pintavorn and Cook, 2008; Kapatou et al.,
2010), induced phospholipidosis – most markedly in B-13/H cells
(Fig. 3C) – a response that increased with exposure time and was es-
sentially irreversible (Fig. 3D). Fig. 3E and F demonstrate that exposing
B-13/H cells to a variety of different cationic amphiphilic drugs
(amiodarone, tamoxifen, chlorpromazine, quinidine and promazine),
but not structurally unrelated drugs (menadione, paracetamol) resulted
in a dose-dependent increase in phospholipidosis that was reduced at
higher (more toxic) concentrations.
3.4. The role of LPLA2 in B-13 cell phospholipidosis
The mechanism leading to the accumulation of phospholipids in
cells exposed to cationic amphiphilic drugs has been proposed to be
associated with an block in lysosomal phospholipase A2 (LPLA2) in-
teraction with lysosomal membranes (and to its subsequent increased
degradation), resulting in an inhibition of phospholipid turnover and
therefore accumulation (Shayman and Abe, 2013).
Fig. 4A confirms that B-13 and B-13/H cells express Lpla2 tran-
scripts similarly to liver and many other tissues and therefore – as-
suming translation to protein – the cells are unlikely to be sensitized to
phospholipidosis due to the absence of functional Lpla2. Fig. 4B de-
monstrates that ectopic expression of human LPLA2 with phospholipi-
dosis-inducing concentrations of tamoxifen in B-13 cells resulted in a
statistically significant reduction of phospholipidosis, supporting a role
for a block of in LPLA2 interaction with lysosomal membranes in
phospholipidosis. This effect was LPLA2-dependent at a fixed con-
centration of tamoxifen, such that transfecting increasing amounts of
LPLA2-encoding plasmid into B-13 cells resulted in a dose-dependent
reduction in phopsholipidosis (Fig. 4C).
3.5. Methapyrilene induces phospholipidosis in B-13 and B-13/H cells
Methapyrilene is a H1 histamine antagonist that was withdrawn
from the market because it was shown to be a non-genotoxic rat liver
carcinogen (Habs et al., 1986). Methapyrilene is also toxic to rat he-
patocytes in vitro (Ratra et al., 1998a) and induces periportal liver
injury when orally administered to rats (Ratra et al., 1998b). Metha-
pyrilene has a cationic amphiphilic structure (Fig. 5A) but has not, to
our knowledge, previously been investigated for its ability to induce
phospholipidosis.
Fig. 5B and C demonstrate that methapyrilene exposure resulted in
phospholipidosis in both B-13 and B-13/H cells in dose-dependent
manners, most potently in B-13 cells. As previously reported (Probert
et al., 2014), methapyrilene was only toxic to B-13/H cells and not to B-
13 cells and similar results were observed in these studies (Fig. 5D).
Previous work has also demonstrated that methapyrilene hepatoxicity
is inhibited by sulfhydryl reducing agents and the Ca2+ channel blocker
nifedipine (Ratra et al., 1998a; Probert et al., 2014). Fig. 5E demon-
strates that methapyrilene-induced phospholipidosis in B-13/H cells
was increased when cells were co-incubated with nifedipine but de-
creased when co-incubated with dithiothreitol (DTT). However, when
phospholipidosis was reduced through DTT – or increased through ni-
fedipine additions – methapyrilene toxicity was unaffected or sig-
nificantly decreased respectively (Fig. 5, lower panel). In contrast, no
significant modulating effects were observed when steatotic B-13/H
Fig. 3. Exposure to cationic amphiphilic drugs results in phospholipidosis in B-13 and B-13/H cells. A, Upper panel, RT-PCR for the indicated transcripts in RNA isolated from the
indicated cell/tissue; lower panel, Western Blot for the indicated proteins in extracts from the indicated cell/tissue. Each lane contains 10 μg protein/lane. B, immunocytochemical
staining for LAMP1 (green) in B-13 and B-13/H cells with DAPI (blue) staining DNA. No 1° Ab control, identical staining procedure with the sole exception of incubation with primary
anti-LAMP1 antibody. C, B-13 or B-13/H cells were treated once for 2 days with medium supplemented with 6.25 μM amiodarone. After 24 h, cells were additionally incubated with
LipidTOX (red) and at 48 h cells were fixed and stained with DAPI (blue) prior to fluorescence imaging as outlined in Methods section. D, B-13/H cells were treated daily (with daily fresh
medium changes) with 6.25 μM amiodarone. Twenty four hours prior to fixation and analysis, cells were also additionally incubated with LipidTOX. Cells were fixed, stained with DAPI
and phospholipidosis quantified and normalised to DAPI fluorescence as outlined in Methods section. Data are the mean and standard deviation of 3 separate determinations from the
same experiment, typical of 2 separate experiments, *significantly different (two tailed) from cells at time zero using ANOVA (p < 0.05) followed by Bonferonni post hoc test. E/F, B-13/
H were treated once for 2 days with medium supplemented with the indicated concentration of drugs. After 24 h, cells were additionally incubated with LipidTOX (red) and at 48 h cells
were fixed and stained with DAPI (blue) and phospholipidosis quantified and normalised to DAPI fluorescence as outlined in Methods section. Data are the mean and standard deviation
of 3 separate determinations from the same experiment, typical of 2 separate experiments, *significantly different phospholipidosis (two tailed) from control treated cells using ANOVA
(p < 0.05) followed by Bonferonni post hoc test. Note, cell viability as determined by MTT assay was significantly reduced compared to untreated cells at 50 μM amiodarone and at
concentrations≥50 μM tamoxifen,≥50 μM tamoxifen,≥100 μM chlorpromazine,≥6.25 μM menadione and≥50 μM promazine. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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cells were treated with methapyrilene (Fig. 5F left panel) and also with
menadione, a toxin that does not cause lipid dysregulation (Fig. 5F,
right panel).
Since B-13 cells develop significant phospholipidosis after metha-
pyrilene exposure but do not undergo cell death and B-13/H cell death
is inhibited by nifedipine but phospholipidosis is increased, these data
suggest that phospholipidosis is not a critical event in methapyrilene-
induced hepatotoxicity. Interestingly, addition of DTT to B-13/H cells
treated with amiodarone or tamoxifen potently blocked the induction of
phospholipidosis (Supp Fig. S4 in the online version at DOI: http://10.
1016/j.tox.2017.05.014(http://dx.doi.org/10.1016/j.tox.2017.05.
014)), suggesting that an oxidative redox status and/or protein thiol
oxidation is necessary for phospholipid accumulation. Addition of DTT
to cultures after induction of phospholipidosis did not affect the
fluorescence readout, confirming that the effect of DTT was cell-
dependent and not associated with a direct chemical interaction with
the detecting fluorophore (e.g. through fluorescence quenching), data
not shown.
4. Discussion
The B-13 cell line is a unique tool for generating hepatocyte-like B-
13/H cells using a simple protocol and in a cost-effective manner.
Expression of many drug metabolising enzymes such as cytochrome
P450 s and conjugating enzymes at levels similar to those present in
intact rat liver remains a prominent feature and has recently been
exploited in toxicity and genotoxicity studies (Marek et al., 2003;
Wallace et al., 2010c; Probert et al., 2015). Many of the drug metabo-
lising enzymes are functional under the simple (e.g. plastic substrata,
2D format, no requirement for recombinant factors) culture metho-
dology employed in the current study though undoubtedly increased
functionality and utility in toxicological studies is likely through
modification of the medium components (e.g. addition of haem pre-
cursors to bolster functional cytochrome P450 levels (Fairhall et al.,
2013a)). However, little attention has been paid to these aspects to
date.
This paper demonstrates for the first time that B-13 cells are
homozygous wild type for the PNPLA3 gene, for which a polymorphism
for susceptibility to NAFLD in man has been identified (Liu et al., 2014).
Nonetheless, B-13/H cells will accumulate intracellular triglycerides in
the form of lipid droplets (steatosis) in response to exposure to high
levels of medium fatty acids (bound to albumin to reduce their toxicity)
or when exposed to the LXR activator T0901317. Storage of neutral
lipids has been shown to be directly proportional to the abundance of
ADFP, a protein residing at the surface of lipid droplets and indicated to
be involved in the metabolism of stored lipids (Chang et al., 2006).
Since GW3965 induces ADFP in human but not in rat hepatocytes, this
may explain why GW3965 activated the LXR in B-13/H cells, but did
not markedly promote steatosis. Interestingly, the B-13 progenitor cell
does not become markedly steatotic in response to fatty acid exposure.
The processes of fatty acid uptake by cells remain to be fully defined.
Despite the presence in some cells of protein transporters, diffusion
remains one route for fatty acids to enter cells. The lack of steatosis in B-
13 cells in response to either fatty acids or T0901317 may be associated
with a lack of CD36 and LXR expression respectively. That B-13/H cells
respond to these challenges by becoming steatotic however, serves to
underpin their functionality as hepatocyte-like, since this is a response
observed in hepatocytes in vivo to these challenges. In addition, we
report for the first time that the both B-13 and B-13/H cells accumulate
phospholipids (phospholipidosis) when exposed to hydrophobic am-
phipathic drugs and that the mechanism at least in part, is associated
with an inhibition and/or degradation of LPLA2.
In all cases, the dysregulated accumulation of lipids (steatosis or
phospholipidosis) show time and dose-response effects.
Given the regulatory requirements for drug and chemical safety
testing (e.g. the Registration, Evaluation, Authorisation & restriction of
Chemicals/REACH), in vitro platform technologies may be the only
practical way to estimate potential adverse effects in man. A major
hurdle to overcome in exploiting these technologies will be to progress
from confirming that a technology correctly predicts known adverse
effects, to accepting that a technology will predict adverse effects of a
chemical in vivo. In this respect, methapyrilene was examined for its
ability to induce phospholipidosis. Methapyrilene was selected because
the liver is a target organ for toxicity to this drug, its chemical structure
includes moieties that are associated with phospholipidosis induction
and because, to our knowledge, this effect had not been previously
examined. We demonstrate that methapyrilene is a potent inducer of
phospholipidosis but that this response likely plays a minimal role in
necrosis since induction is greater in B-13 cells, which were insensitive
to methapyrilene toxicity. Furthermore, compounds which blocked
methapyriline toxicity in B-13/H cells also increased the accumulation
of phospholipids. Given the simplicity of generation, this paper de-
monstrates that B-13/H cells are an effective model cell system in which
to study hepatic lipid dysregulation in response to elevated fatty acids,
LXR activators and chemicals capable of inducing phospholipidosis.
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Fig. 4. Human LPLA2 expression reduces tamoxifen-induced phospholipiosis in B-13 cells. A, RT-PCR for indicated transcripts in the indicate cell types or rat tissues. B, Western Blot in
extracts from B-13 cells transfected with the indicated construct. Each lane contains 10 μg protein/lane (Left Panel). Right Panel, B-13 cells transfected as indicated with pcDNA empty
vector or pcDNA-LPLA2 as outlined in the Methods section and after 24 h the cells were treated with indicated doses of tamoxifen and additionally incubated with LipidTOX (red). After a
further 24 h, the cells were fixed and stained with DAPI (blue) and phospholipidosis quantified and normalised to DAPI fluorescence as outlined in the Methods section, *significantly
different phospholipidosis (two tailed) from cells transfected with pcDNA-empty using the Student’s T test (p < 0.05). C, B-13 cells were transfected with indicated concentrations of
pcDNA-LPLA2 and RL-TK to a final concentration of 2 μg per well as outlined in the Methods section and after 24 h, the cells were treated with 6 μM tamoxifen. After a further 24 h,
phospholipidosis and renilla activities were determined (separate samples). Significantly different *phospholipidosis or $renilla activity (two tailed) versus cell transfected in the absence
of LPLA2 or RL-TK respectively using ANOVA (p < 0.05) followed by Bonferonni post hoc test. (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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Fig. 5. Methapyrilene exposure causes phospholipidosis in B-13 and B-13/H cells. A, structure of methapyrilene. B, B-13 or B-13/H cells were treated once for 2 days with medium
supplemented with methapyrilene. After 24 h, cells were additionally incubated with LipidTOX (red) and at 48 h cells were fixed and stained with DAPI (blue) prior to fluorescence
imaging as outlined in Methods section. C, B-13 or B-13/H cells were treated once for 2 days with medium supplemented with the indicated concentration of drugs. After 24 h, cells were
additionally incubated with LipidTOX (red) and at 48 h cells were fixed and stained with DAPI (blue) and phospholipidosis quantified and normalised to DAPI fluorescence as outlined in
Methods section. Data are the mean and standard deviation of 3 separate determinations from the same experiment, typical of 3 separate experiments, significantly different phos-
pholipidosis (two tailed) from *control treated cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test or #versus B-13 cells treated with the same concentration of
methapyrilene using the Student’s T test (two tailed) (p < 0.05). D, B-13 and B-13/H cells treated as in C. After 46 h, cells were incubated with MTT for 2 h and reduction determined as
outlined in Methods section prior to protein determination. Data are the mean and standard deviation MTT activity normalised to cell protein of 3 separate determinations from the same
experiment, typical of 2 separate experiments, significantly different MTT activity (two tailed) from *control treated cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test
or #versus B-13 cells treated with the same concentration of methapyrilene using the Student’s T test (two tailed) (p < 0.05). E, Upper panel – B-13/H cells were pre-incubated with
indicated treatment for 4 h and then re-treated with where indicated, 200 μMmethapyrilene, for 24 h. The cells were then incubated with LipidTOX (red) and at 48 h, cells were fixed and
stained with DAPI (blue) and phospholipidosis quantified and normalised to DAPI fluorescence as outlined in Methods section. Lower panel – B-13/H cells were pre-incubated as above
and at 46 h, cells were incubated with MTT for the final 2 h and reduction determined as outlined in the methods section. Data are the mean and standard deviation MTT activity
normalised to cell protein of 3 separate determinations from the same experiment, typical of 2 separate experiments. Significantly different (two tailed) phosholipidosis versus *control
treated or #methapyrilene only treated cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test. F, B-13/H cells were pre-treated with BSA or 1 mM fatty acids for 24 h to
induce steatosis, washed and then incubated methapyrilene or menadione for 24 h in normal medium. Cells were incubated with MTT for 2 h and reduction determined as outlined in the
Methods section. Data are the mean and standard deviation MTT activity normalised to cell protein of 5 separate determination from the same experiment, typical of 3 separate
experiments. *Significantly different (two tailed) MTT activity versus control treated cells using ANOVA (p < 0.05) followed by Bonferonni post hoc test. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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